S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:CVRX

CVRx (CVRX) Stock Price, News & Analysis

$14.90
-0.36 (-2.36%)
(As of 04/19/2024 ET)
Today's Range
$14.68
$15.57
50-Day Range
$14.90
$23.61
52-Week Range
$9.07
$33.13
Volume
109,424 shs
Average Volume
119,741 shs
Market Capitalization
$321.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.67

CVRx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
126.0% Upside
$33.67 Price Target
Short Interest
Bearish
8.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of CVRx in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$151,903 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

Medical Sector

468th out of 909 stocks

Surgical & Medical Instruments Industry

55th out of 96 stocks

CVRX stock logo

About CVRx Stock (NASDAQ:CVRX)

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRX Stock Price History

CVRX Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Craig-Hallum Reaffirms Their Hold Rating on ProSomnus (OSA)
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
CVRX Mar 2024 30.000 call
CVRX Mar 2024 20.000 put
CVRx names Kevin Hykes as CEO
Piper Sandler Keeps Their Buy Rating on CVRx (CVRX)
CVRx Full Year 2023 Earnings: EPS Beats Expectations
CVRx Names Board Member Kevin Hykes President, CEO
Bio-Techne (TECH) Receives a Buy from Craig-Hallum
CVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Call Transcript
Q4 2023 CVRx Inc Earnings Call
CVRx: Q4 Earnings Insights
Earnings Outlook For CVRx
See More Headlines
Receive CVRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/25/2024
Today
4/20/2024
Next Earnings (Confirmed)
4/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CVRX
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.67
High Stock Price Target
$36.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+126.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-41,200,000.00
Net Margins
-104.85%
Pretax Margin
-104.47%

Debt

Sales & Book Value

Annual Sales
$39.29 million
Book Value
$3.65 per share

Miscellaneous

Free Float
17,643,000
Market Cap
$321.69 million
Optionable
Optionable
Beta
1.29
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Kevin Hykes (Age 58)
    President, CEO & Director
  • Mr. Jared Oasheim (Age 40)
    Chief Financial Officer
    Comp: $446.1k
  • Mr. Paul Verrastro (Age 61)
    Chief Marketing & Strategy Officer
    Comp: $529.84k
  • Mr. Paul Pignato
    Vice President of Operations
  • Ms. Jonelle R. Burnham (Age 53)
    Vice President & General Counsel
  • Mr. Craig Palmer (Age 47)
    Senior Vice President of US Sales

CVRX Stock Analysis - Frequently Asked Questions

Should I buy or sell CVRx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CVRx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CVRX shares.
View CVRX analyst ratings
or view top-rated stocks.

What is CVRx's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price objectives for CVRx's shares. Their CVRX share price targets range from $32.00 to $36.00. On average, they expect the company's stock price to reach $33.67 in the next year. This suggests a possible upside of 126.0% from the stock's current price.
View analysts price targets for CVRX
or view top-rated stocks among Wall Street analysts.

How have CVRX shares performed in 2024?

CVRx's stock was trading at $31.44 at the start of the year. Since then, CVRX stock has decreased by 52.6% and is now trading at $14.90.
View the best growth stocks for 2024 here
.

When is CVRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our CVRX earnings forecast
.

How can I listen to CVRx's earnings call?

CVRx will be holding an earnings conference call on Tuesday, April 30th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were CVRx's earnings last quarter?

CVRx, Inc. (NASDAQ:CVRX) announced its quarterly earnings results on Thursday, January, 25th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.11. The firm earned $11.31 million during the quarter, compared to the consensus estimate of $10.90 million. CVRx had a negative trailing twelve-month return on equity of 47.30% and a negative net margin of 104.85%.

What guidance has CVRx issued on next quarter's earnings?

CVRx issued an update on its first quarter 2024 earnings guidance on Friday, January, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $11.0 million-$12.0 million, compared to the consensus revenue estimate of $11.6 million.

When did CVRx IPO?

CVRx (CVRX) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

Who are CVRx's major shareholders?

CVRx's stock is owned by many different institutional and retail investors. Top institutional shareholders include GSG Advisors LLC (0.17%). Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen, Mudit K Jain, Nea Partners 10 L P and Paul Verrastro.
View institutional ownership trends
.

How do I buy shares of CVRx?

Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVRX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners